Literature DB >> 19759250

Recombinant Sindbis virus vectors designed to express protective antigen of Bacillus anthracis protect animals from anthrax and display synergy with ciprofloxacin.

John M Thomas1, Scott T Moen, Bryan T Gnade, Diego A Vargas-Inchaustegui, Sheri M Foltz, Giovanni Suarez, Hans W Heidner, Rolf König, Ashok K Chopra, Johnny W Peterson.   

Abstract

Recombinant Sindbis viruses were engineered to express alternative forms of the protective antigen (PA) of Bacillus anthracis. The recombinant viruses induced PA-specific immunoglobulin G and neutralizing antibodies in Swiss Webster mice. Vaccination with the recombinant viruses induced immunity that offered some protection from a lethal Ames strain spore challenge and synergized the protective effects of ciprofloxacin.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19759250      PMCID： PMC2772374          DOI： 10.1128/CVI.00173-09

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  19 in total

Review 1.  CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine.

Authors:  Dennis M Klinman; Hang Xie; Bruce E Ivins
Journal:  Ann N Y Acad Sci       Date:  2006-10       Impact factor: 5.691

2.  CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine.

Authors:  Hang Xie; Ihsan Gursel; Bruce E Ivins; Manmohan Singh; Derek T O'Hagan; Jeffrey B Ulmer; Dennis M Klinman
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

3.  Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor.

Authors:  Heather M Scobie; G Jonah A Rainey; Kenneth A Bradley; John A T Young
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-16       Impact factor: 11.205

4.  Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax.

Authors:  Johnny W Peterson; Jason E Comer; David M Noffsinger; Autumn Wenglikowski; Kristin G Walberg; Bagram M Chatuev; Ashok K Chopra; Lawrence R Stanberry; Angray S Kang; Wolfgang W Scholz; Jagadish Sircar
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

5.  In vitro correlate of immunity in an animal model of inhalational anthrax

Authors: 
Journal:  J Appl Microbiol       Date:  1999-08       Impact factor: 3.772

6.  pH-dependent permeabilization of the plasma membrane of mammalian cells by anthrax protective antigen.

Authors:  J C Milne; R J Collier
Journal:  Mol Microbiol       Date:  1993-11       Impact factor: 3.501

7.  An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals.

Authors:  John F Hewetson; Stephen F Little; Bruce E Ivins; Wendy M Johnson; Phillip R Pittman; J Edward Brown; Sarah L Norris; Carl J Nielsen
Journal:  Vaccine       Date:  2008-06-12       Impact factor: 3.641

8.  Characterization of macrophage sensitivity and resistance to anthrax lethal toxin.

Authors:  A M Friedlander; R Bhatnagar; S H Leppla; L Johnson; Y Singh
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

9.  Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.

Authors:  H S Heine; J Bassett; L Miller; A Bassett; B E Ivins; D Lehoux; F F Arhin; T R Parr; G Moeck
Journal:  Antimicrob Agents Chemother       Date:  2008-07-07       Impact factor: 5.191

10.  Inhibitors of receptor-mediated endocytosis block the entry of Bacillus anthracis adenylate cyclase toxin but not that of Bordetella pertussis adenylate cyclase toxin.

Authors:  V M Gordon; S H Leppla; E L Hewlett
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441
View more
  4 in total

Review 1.  Alphavirus-based vaccines.

Authors:  Kenneth Lundstrom
Journal:  Viruses       Date:  2014-06-16       Impact factor: 5.048

Review 2.  Replicon RNA Viral Vectors as Vaccines.

Authors:  Kenneth Lundstrom
Journal:  Vaccines (Basel)       Date:  2016-11-07

Review 3.  RNA-based drugs and vaccines.

Authors:  Kenneth Lundstrom
Journal:  Expert Rev Vaccines       Date:  2014-09-14       Impact factor: 5.217

Review 4.  Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19.

Authors:  Kenneth Lundstrom
Journal:  Viruses       Date:  2020-11-18       Impact factor: 5.048
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.